Dr. Donald Kohn has been developing gene therapies for rare pediatric immune disorders for over 30 years. This week, his role in a clinical trial has culminated in the first-ever U.S. Food and Drug ...
Botstein, Princeton’s Anthony B. Evnin ‘62 Professor of Genomics, Emeritus, and an emeritus professor of molecular biology ...
Respondents to a survey note an urgent need for role-specific training to bridge knowledge gaps in advanced-therapy ...
Marne-cel now offers an option to children with the rare immune disorder who lack a sibling donor for stem cell ...
Collaboration Leverages Made Scientific's Industry Expertise and Workforce Development Initiative to Empower the Next Generation of Cell and Gene Therapy Professionals PRINCETON, N.J. and NEWARK, N.J.
CRISPR is a powerful DNA-editing tool that has underpinned huge advancements in human health care in the last decade. It is a ...
Learn how synthetic promoters bring innovation to gene expression, enhancing performance and safety in biotechnology ...
Scientists have developed a new gene therapy that quiets pain at its source in the brain—without the addictive risks of opioids. Using AI to map how pain is processed, they created a targeted “off ...
Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...
Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< ...
All eyes are on biopharmaceutical firm Ocugen today. The company has scheduled a presentation for 2:00 PM CET on Tuesday, ...
Even with early treatment, infants and toddlers with SMA have problems with swallowing skills compared with healthy children, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results